HOWLHealthcare · BiotechnologyThe 1 Wall Street analysts covering Werewolf Therapeutics, Inc. hold a median 12-month price target of $7 — +593.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 21 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Werewolf Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (46): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HOWL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +593.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $10 → $4.00 |
| 18 Nov 2025 | B of A Securities | Maintains | Buy | — |
| 25 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 21 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 9 May 2025 | Wedbush | Maintains | Outperform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Wedbush | Reiterates | Outperform | — |
| 14 Jan 2025 | JMP Securities | Maintains | Market Outperform | — |
| 19 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 June 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 4 June 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 3 Apr 2024 | JMP Securities | Initiates | Market Outperform | — |
| 7 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HOWL appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Werewolf Therapeutics, Inc. returned −36.5% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 47% of US stocks
Cheaper than 30% of US stocks
Cheaper than 70% of US stocks
Higher than 92% of US stocks
Higher than 3% of US stocks
Higher than 11% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Werewolf Therapeutics, Inc. has a market value of $50.1M and an enterprise value of $28.1M.
Revenue in the twelve months to 30 June 2026: $21.0M.
Net income over the same four quarters: −$34.6M, a −164.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.76.
Free cash flow in the twelve months to 30 June 2026: −$30.1M.
Trailing P/E: −0.8×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Werewolf Therapeutics, Inc. employs 39 people — $538K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Werewolf Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks upgraded Werewolf Therapeutics (HOWL) to Rank #1 (Strong Buy), citing growing optimism about the company’s earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — HOWL watchers may note the upgrade as a change in Zacks’ assessment of the company’s earnings prospects.
Zacks Investment Research added HOWL, along with LITE, PERI, GSBD and GFF, to its Zacks Rank #1 (Strong Buy) List on October 9, 2026.
Why it matters — HOWL watchers may note the stock's inclusion on Zacks' top-ranked list.
Brodsky & Smith issued a shareholder reminder notifying investors of an investigation involving Werewolf Therapeutics, Inc. (Nasdaq: HOWL), along with Beazer Homes, Lantheus Holdings, and MarketAxess Holdings. The law firm invites shareholders to contact it about the investigation at no cost.
Why it matters — HOWL investors may want to monitor the announced investigation as it could relate to potential concerns regarding the company's disclosures or practices.
Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving several companies, including Werewolf Therapeutics, Inc. (HOWL). The firm invites shareholders to discuss the matter at no cost.
Why it matters — The investigation announcement signals potential legal or governance scrutiny involving Werewolf Therapeutics that shareholders may want to monitor.
Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving Werewolf Therapeutics and several other companies. The notice invites shareholders who own shares to contact the firm at no cost to discuss the investigation.
Why it matters — A law firm's investigation notice relating to Werewolf Therapeutics could signal potential shareholder concern or legal scrutiny regarding the company, which may be relevant for HOWL investors to monitor.
The 1 Wall Street analysts covering Werewolf Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Werewolf Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Werewolf Therapeutics, Inc. 88 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, Werewolf Therapeutics, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +593.1% from the last close, and Ticker Nerd's factor model ranks Werewolf Therapeutics, Inc. 88 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Werewolf Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HOWL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Werewolf Therapeutics, Inc. returned -36.5% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions.
The most recent item we track (Zacks Investment Research, 13 Oct 2026): "Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why". Zacks upgraded Werewolf Therapeutics (HOWL) to Rank #1 (Strong Buy), citing growing optimism about the company’s earnings prospects. The excerpt says this might drive the stock higher in the near term.
Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue. Its pipeline includes immune-modulating candidates aimed at solid tumors and specific cancer targets, reflecting a concentration on oncology and immunotherapy. Werewolf Therapeutics Inc. operates as a clinical-stage developer of advanced biologic therapies, with research and development activities spanning tumor-directed immune activation and targeted protein engineering. Headquartered in Watertown, Massachusetts, the company is positioned within the biotechnology sector as a specialist in next-generation cancer therapeutics.
CEO Dr. Daniel J. Hicklin Ph.D. · 39 employees · United States · https://werewolftx.com
